Does androgen-deprivation therapy for prostate cancer increase the risk for thromboembolic disease?

被引：0
|
作者：
Pinthus, Jehonathan H. [1 ]
Duivenvoorden, Wilhelmina C. [1 ]
机构：
[1] McMaster Univ, Div Urol, Dept Surg, Hamilton, ON, Canada
来源：
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL | 2017年 / 11卷 / 1-2期
关键词：
VENOUS THROMBOEMBOLISM;
D O I：
10.5489/cuaj.4394
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：39 / 40
页数：2
相关论文
共 50 条
  • [31] Review: Androgen deprivation therapy does not increase CV mortality in prostate cancer
    Canfield, Steven E.
    Dahm, Philipp
    ANNALS OF INTERNAL MEDICINE, 2012, 156 (08)
  • [32] Does androgen deprivation therapy in men with prostate cancer increase cardiovascular morbidity?
    Corsello, Steven M.
    Kantoff, Philip W.
    NATURE CLINICAL PRACTICE UROLOGY, 2008, 5 (02): : 80 - 81
  • [33] Does androgen-deprivation therapy increase the risk of ischemic cardiovascular and cerebrovascular diseases in patients with prostate cancer? A nationwide population-based cohort study
    Kim, Do Kyung
    Lee, Hye Sun
    Park, Ju-Young
    Kim, Jong Won
    Ha, Ji Soo
    Kim, Jae Heon
    Yang, Won Jae
    Cho, Kang Su
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (04) : 1217 - 1226
  • [34] Androgen-Deprivation Therapy for Nonmetastatic Prostate Cancer Is Associated With an Increased Risk of Peripheral Arterial Disease and Venous Thromboembolism
    Hu, Jim C.
    Williams, Stephen B.
    O'Malley, A. James
    Smith, Matthew R.
    Nguyen, Paul L.
    Keating, Nancy L.
    EUROPEAN UROLOGY, 2012, 61 (06) : 1119 - 1128
  • [35] Does androgen-deprivation therapy increase the risk of ischemic cardiovascular and cerebrovascular diseases in patients with prostate cancer? A nationwide population-based cohort study
    Do Kyung Kim
    Hye Sun Lee
    Ju-Young Park
    Jong Won Kim
    Ji Soo Ha
    Jae Heon Kim
    Won Jae Yang
    Kang Su Cho
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 1217 - 1226
  • [36] Re: Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
    不详
    JOURNAL OF UROLOGY, 2021, 205 (01): : 303 - 304
  • [37] Age and androgen-deprivation therapy on exercise outcomes in men with prostate cancer
    Alberga, Angela S.
    Segal, Roanne J.
    Reid, Robert D.
    Scott, Chris G.
    Sigal, Ronald J.
    Khandwala, Farah
    Jaffey, James
    Wells, George A.
    Kenny, Glen P.
    SUPPORTIVE CARE IN CANCER, 2012, 20 (05) : 971 - 981
  • [38] A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients
    C Jin
    Y Fan
    Y Meng
    C Shen
    Y Wang
    S Hu
    C Cui
    T Xu
    W Yu
    J Jin
    Prostate Cancer and Prostatic Diseases, 2016, 19 : 333 - 339
  • [39] Harms of Intermittent vs Continuous Androgen-Deprivation Therapy for Prostate Cancer
    Niraula, Saroj
    Tannock, Ian F.
    JAMA ONCOLOGY, 2016, 2 (04) : 461 - 462
  • [40] Immediate versus deferred androgen-deprivation therapy for localized prostate cancer
    Nature Clinical Practice Urology, 2006, 3 (7): : 348 - 349
12345